Annotated abstract

Lecanemab’s benefits are too small and uncertain

bmj · 2026-02-11 · canonical JSON source

1 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

The competing interest statement of this article by Robert Howard (BMJ 2024;386:q2044, doi:10.1136/bmj.q2044) has been amended to note that he was an unpaid member of the scientific board of Synaptogenix. The article has now been recategorised as an Opinion.